Prestige BioPharma Limited (KRX:950210)
South Korea · Delayed Price · Currency is KRW 6,310.00
-280.00 (-4.25%)
Last updated: Jun 22, 2026, 1:37 PM KST
Prestige BioPharma Market Cap
Prestige BioPharma has a market cap or net worth of 79.21 billion as of June 18, 2026. Its market cap has decreased by -49.92% in one year.
Market Cap
79.21B
Enterprise Value
183.47B
Revenue
16.21B
Ranking
n/a
PE Ratio
n/a
Stock Price
6,310.00
Market Cap Chart
Since May 28, 2021, Prestige BioPharma's market cap has decreased from 360.58B to 79.21B, a decrease of -78.03%. That is a compound annual growth rate of -25.87%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jun 19, 2026 | 79.21B | -48.72% |
| Dec 30, 2025 | 154.45B | -14.96% |
| Dec 30, 2024 | 181.61B | 59.39% |
| Dec 28, 2023 | 113.94B | 29.33% |
| Dec 29, 2022 | 88.10B | -64.84% |
| Dec 30, 2021 | 250.60B | -30.50% |
| May 28, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Genexine | 125.52B |
| MedPacto | 115.16B |
| Vaxcell-Bio Therapeutics | 106.63B |
| Amicogen | 106.60B |
| ENCell | 91.43B |
| iNtRON Biotechnology | 84.09B |
| CG Invites | 79.20B |
| GeneOne Life Science | 62.93B |